Alexza Pharmaceuticals, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2001-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.alexza.com
Clinical Trials
34
Active:0
Completed:32
Trial Phases
4 Phases
Phase 1:17
Phase 2:9
Phase 3:2
+1 more phases
Drug Approvals
1
FDA:1
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (30 trials with phase data)• Click on a phase to view related trials
Phase 1
17 (56.7%)Phase 2
9 (30.0%)Phase 3
2 (6.7%)Phase 4
2 (6.7%)Study to Evaluate the Efficacy and Safety of Staccato Apomorphine (AZ-009) in Patients With Parkinson's Disease Experiencing OFF Episodes
- First Posted Date
- 2023-08-07
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Alexza Pharmaceuticals, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT05979415
- Locations
- 🇺🇸
Movement Disorders Center of Arizona, Scottsdale, Arizona, United States
🇺🇸Tuscon Neuroscience Research (M3 Wake Research), Tucson, Arizona, United States
🇺🇸The Parkinson's and Movement Disorder Institute, Fountain Valley, California, United States
Staccato Granisetron® (AZ 010) for the Treatment of Cyclic Vomiting Syndrome
Phase 2
Completed
- Conditions
- Cyclic Vomiting Syndrome
- First Posted Date
- 2020-11-27
- Last Posted Date
- 2025-06-11
- Lead Sponsor
- Alexza Pharmaceuticals, Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT04645953
- Locations
- 🇺🇸
Om Research, Lancaster, California, United States
🇺🇸Axis Clinical Trials, Los Angeles, California, United States
🇺🇸Precision Research Institute, LLC, San Diego, California, United States
Staccato® Granisetron Multiple Dose PK
Phase 1
Completed
- Conditions
- Healthy
- First Posted Date
- 2020-03-31
- Last Posted Date
- 2020-10-30
- Lead Sponsor
- Alexza Pharmaceuticals, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT04327765
- Locations
- 🇺🇸
Celerion, Tempe, Arizona, United States
Staccato® Granisetron Single Dose PK
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Combination Product: 0.5mg AZ-010; placeboCombination Product: 3mg AZ-010Combination Product: AZ-010 1mgCombination Product: 1mg AZ-010Other: PlaceboDrug: IV Granisetron 1mg
- First Posted Date
- 2019-12-16
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- Alexza Pharmaceuticals, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT04200092
- Locations
- 🇺🇸
Celerion, Tempe, Arizona, United States
Staccato Apomorphine Multi-dose PK and PD in Patients With Parkinson's Disease
Phase 1
Completed
- Conditions
- Parkinson's Disease
- Interventions
- Drug: 009-A2Drug: 009-A0Drug: 009-B2 (placebo --> active) crossoverDrug: 009-A1Drug: 009-A3Drug: 009-B1 (active --> placebo) crossover
- First Posted Date
- 2019-11-08
- Last Posted Date
- 2020-11-04
- Lead Sponsor
- Alexza Pharmaceuticals, Inc.
- Target Recruit Count
- 35
- Registration Number
- NCT04157933
- Locations
- 🇳🇱
Centre for Human Drug Research, Leiden, Netherlands
- Prev
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- Next
News
No news found